Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wee, Jee Wan | - |
dc.contributor.author | Jeon, Young Woo | - |
dc.contributor.author | Eun, Jun Young | - |
dc.contributor.author | Kim, Han Jo | - |
dc.contributor.author | Bae, Sang Byung | - |
dc.contributor.author | Lee, Kyu Taek | - |
dc.date.accessioned | 2021-08-11T22:26:45Z | - |
dc.date.available | 2021-08-11T22:26:45Z | - |
dc.date.issued | 2014-09 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.issn | 2288-0011 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/11940 | - |
dc.description.abstract | Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder that leads to mucocutaneous telangiectasias, epistaxis, and gastrointestinal bleeding. Depending on the severity and manifestation of the disease, various therapeutic modalities have been used, from local bleeding control to surgery or concomitant drug therapy. Several articles under review have presented guidelines for treatment of HHT with bevacizumab as a direct anti-angiogenesis strategy. Still, neither the exact optimal dose nor the minimum effective dose of intravenous bevacizumab in patients with severe HHT has been reported. A 55-year-old man presented with long-standing epistaxis, recent melena, dizziness, and a three-generation family history of chronic epistaxis, anemia, and regular blood transfusions. Treatment with argon plasma coagulation (APC) for the gastrointestinal bleeding failed to raise hemoglobin levels, we considered using the bevacizumab. We report a patient with severe HHT, who was treated with low-dose bevacizumab (2 mg/kg) and improved substantially. | - |
dc.format.extent | 4 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한혈액학회 | - |
dc.title | Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5045/br.2014.49.3.192 | - |
dc.identifier.scopusid | 2-s2.0-84911385214 | - |
dc.identifier.wosid | 000433685300013 | - |
dc.identifier.bibliographicCitation | Blood Research, v.49, no.3, pp 192 - 195 | - |
dc.citation.title | Blood Research | - |
dc.citation.volume | 49 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 192 | - |
dc.citation.endPage | 195 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001911598 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PATIENT | - |
dc.subject.keywordAuthor | Bevacizumab | - |
dc.subject.keywordAuthor | Hereditary hemorrhagic telangiectasia | - |
dc.subject.keywordAuthor | Low dose | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.